Osteoarthritis (OA) is a painful, degenerative condition that is characterized by the gradual development of joint pain, as well as joint stiffness and limitation of movement in the joints. Of these symptoms, the chief complaint among individuals with OA is pain, which we estimate affected nearly 65 million individuals in the United States and Europe in 2016. Despite multiple available therapies spanning several drug classes, no truly novel therapies effective at treating OA pain have launched in more than a decade, and existing analgesics’ efficacy and/or safety and tolerability profiles leave room for improvement.
Questions Answered:
What are the main treatment drivers and goals for OA pain?
What are surveyed rheumatologists’ opinions of the relative performance of select therapies, including celecoxib (Pfizer’s Celebrex, generics) and Vivlodex (Iroko), on key efficacy, safety/tolerability, and convenience of administration attributes related to OA pain?
Which clinical attributes are key influencers of physician prescribing decisions, which have limited impact, and which are hidden opportunities?
What trade-offs in price and drug performance across select clinical attributes are acceptable to U.S. and European rheumatologists for a hypothetical new OA pain drug?
Product Description
Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.